Aratana Therapeutics Inc. to Report Third Quarter Financial Results
Conference Call and Webcast scheduled for November 11, 2014, 8:30 a.m. ET
KANSAS CITY, Kan. and BOSTON, Nov. 4, 2014 /PRNewswire/ -- Aratana Therapeutics, Inc. (Nasdaq: PETX), a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for companion animals, will host a conference call and live audio webcast on Tuesday, November 11, 2014, at 8:30 a.m. ET, to discuss its financial results for the quarter ended September 30, 2014.
Conference Call Information:
Interested participants and investors may access the conference call by dialing:
- 1 (866) 364-3820 (U.S.)
- 1 (855) 669-9657 (Canada)
- 1 (412) 902-4210 (international)
A replay of the call will be available for 90 days beginning at approximately 10:30 a.m. ET on November 11, 2014. Access numbers for this replay are:
- 1 (877) 344-7529 (U.S.)
- 1 (855) 669-9658 (Canada)
- 1 (412) 317-0088 (international)
- Conference ID: 10055885
An audio webcast will be also accessible via the Investors Relations section of the Aratana Therapeutics website aratana.investorroom.com. The webcast replay will also remain available for 90 days.
About Aratana Therapeutics
Aratana Therapeutics is a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for companion animals. Aratana believes that it can leverage the investment in the human biopharmaceutical industry to bring therapeutics to pets in a capital and time efficient manner. The company's pipeline includes more than fifteen therapeutic candidates targeting pain, inappetence, cancer, viral diseases, allergy and other serious medical conditions. Aratana believes the development and commercialization of these therapeutics will permit veterinarians and pet owners to manage pets' medical needs safely and effectively, resulting in longer and improved quality of life for pets. For more information, please visit www.aratana.com.
SOURCE Aratana Therapeutics, Inc.